CD19 and diffuse large B-cell lymphoma: In total, six CAR-Ts have been approved, four of which are directed against CD19 in B-cell malignancies, primarily diffuse large B-cell lymphoma (DLBCL): axicabtagene ciloleucel (YESCARTA®) [49], tisagenlecleucel (KYMRIAH®) [50], brexucabtagene autoleucel (TECARTUS®) [51].